Research and Development

Showing 15 posts of 9190 posts found.

Pfizer shares update on DMD gene therapy clinical trial

June 13, 2024 Research and Development DMD, Musculo-skeletal disorder, Pfizer, duchenne muscular dystropy, gene therapy

Pfizer has announced an update from its phase 3 randomised, multicentre, double-blind, placebo-controlled CIFFREO trial, which assessed the investigational mini-dystrophin …

Cara Therapeutics shares data from part a of notalgia paresthetica trial

June 13, 2024 Research and Development Cara Therapeutics, Neurology, clinical trial, notalgia paresthetica, pruritus

Cara Therapeutics has announced the outcome from the dose-finding Part A of the KOURAGE-1 study which assessed the efficacy and …

Evotec shares progress in Bristol Myers Squibb neuroscience collaboration

June 12, 2024 Research and Development Evotec, Neurology, bristol myers squibb, neuroscience

Evotec has announced that it has reached important scientific progress within the neuroscience collaboration with Bristol Myers Squibb, initiating a …

Eli Lilly shares results for tirzepatide for MASH resolution

June 10, 2024 Research and Development Eli Lilly, Hepatology, MASH, clinical trial, liver

Eli Lilly has announced results from the phase 2 SYNERGY-NASH study which assessed 190 patients, with or without type 2 …

Nuclera gains £1.14m funding from Innovate UK

June 7, 2024 Research and Development Innovate UK, Nuclera, Pharmacy, grants

Nuclera has announced that it has been awarded two grants from Innovate UK, totalling £1.14m.

Syngene launches new platform for protein production

June 6, 2024 Research and Development ExcellGene, Pharmacy, Syngene, platform, protein production

Syngene has announced the launch of its new protein production platform, which will utilise a cell line and transposon-based technology …

Gilead shares results from two-year analysis of phase 3 study in primary biliary cholangitis

June 5, 2024 Research and Development Gilead, Hepatology, clinical trials, primary biliary cholangitis, seladelpar

Gilead has announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary …
testalize-me-0je8ynv4mis-unsplash

Sanofi shares phase 3 trial results for Sarclisa in multiple myeloma treatment

June 5, 2024 Research and Development Oncology, Sanofi, Sarclisa, clinical trial, multiple myeloma

Sanofi has announced data from the IMROZ phase 3 trial which assessed Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide …

Gilead and Arcus announce results from colorectal cancer treatment trial

June 3, 2024 Research and Development Arcus, Gilead, Oncology, clinical trial, colorectal cancer

Gilead Sciences and Arcus Biosciences have announced new data from cohort B of ARC-9, a phase 1b/2 study which aims …

OSE Immunotherapeutics and Boehringer Ingelheim collaborate on cancer and cardio-renal-metabolic disease treatments

May 24, 2024 Research and Development Boehringer Ingelheim, Cancer, Cardiology, OSE Immunotherapeutics, cardio-renal-metabolic diseases

OSE Immunotherapeutics and Boehringer Ingelheim have announced a major expansion of their existing partnership. The expansion includes two new projects …

Nona Biosciences announced agreement with AstraZeneca for tumour targeted therapies

May 24, 2024 Research and Development AstraZeneca, Cancer, Oncology, nona biosciences, targeted therapies

Nona Biosciences and AstraZeneca have announced that the two companies have entered into a license agreement for preclinical monoclonal antibodies, …

Sanofi, Formation Bio and OpenAI enter AI collaboration

May 22, 2024 Research and Development Formation Bio, OpenAI, Pharmacy, Sanofi, collaboration

Sanofi, Formation Bio and OpenAI have announced that they have entered into a collaboration with the aim of building AI-powered …

GSK shares positive results from phase 3 asthma trials

May 21, 2024 Research and Development Asthma & COPD, GSK, asthma, clinical trial

GSK has announced positive headline results from its phase 3 SWIFT-1 and SWIFT-2 trials, which evaluated the safety and efficacy …

ERS Genomics and IRBM sign license agreement for CRISPR/Cas9

May 20, 2024 Research and Development CRISPR/Cas9, ERS Genomics, IRBM, License Agreement, Pharmacy

ERS Genomics and IRBM have announced that they have entered into a non-exclusive CRISPR/Cas9 license agreement, granting IRBM access to …
diana-polekhina-zbsthwt9vlc-unsplash_2

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024 Research and Development AstraZeneca, COVID-19, Immunology, clinical trial

AstraZeneca has announced positive high-level results from the SUPERNOVA phase 3 trial for a COVID-19 pre-exposure prophylaxis treatment, sipavibart (formerly …

Latest content